TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: AUC0-inf of Monomethyl Fumarate (MMF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Monomethyl Fumarate (MMF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough Forced Expiratory Volume in One Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: score on an IIEF-5
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Aberrant Behavior Checklist (ABC) - Parent Reported Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Aberrant Behavior Checklist (ABC) - Teacher Reported Change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemoglobin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Within Pre-defined Range of Hemoglobin Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average Methoxy Polyethylene Glycol-epoetin Beta Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diameter of colon/rectal wall at surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fibrinolytic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PD20 histamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes from baseline Liver Stiffness measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory Infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Brief pain inventory
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Free-living glycemic regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Hyaluronate Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of vertebral fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Variation of plasma oxytocin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Vessel density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in naming nouns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in naming action verbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in sentence production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Retention rate of RA patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: safety and efficacy of transvaginal NOTES procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement of negative symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Glutamate levels in prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutathione levels in prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of celiac disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Unexpected return To The Operation Room
Endpoint domain: Adverse events/effects
Primary endpoint: Change in FEV1 AUC0-12h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tolerability of AC 170 0.24%
Endpoint domain: Adverse events/effects
Primary endpoint: Numerical rating scale measurement of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of regular smokers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced Substance Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved Treatment Retention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Survival With Good Neurobehavioral Outcome
Endpoint domain: Mortality/survival
Primary endpoint: Benefit from drug as demonstrated by radiographic evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Benefit from drug as demonstrated by clinical evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive attentional tasks performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cerebral functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Brachial Artery Flow-Mediated Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of grade 2-4 and grade 3-4 acute GVHD by day 100
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of overall chronic GVHD and moderate to severe chronic GVHD by 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of late onset acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of topical norepinephrine application
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the percentage of prescriptions containing an antibiotic
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the cost of antibiotic prescription
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Freedom From Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Major Device Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in urine citrate content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of Laboratory Tumor Lysis Syndrome (LTLS)
Endpoint domain: Adverse events/effects
Primary endpoint: Normalization of Uric Acid Levels (UAL) Within 24 Hours of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary sodium excretion concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postoperative Numeric Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Weeks With Platelet Count Greater Than or Equal to 50 x 10^9/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of subjects with recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Change in level of aggressive behaviour in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of dysfunctional parenting
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in frequency of positive parenting and effective discipline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: New or worsening back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: incidence of combined death and necrotizing enterocolitis
Endpoint domain: Mortality/survival
Primary endpoint: Hand displacement during each session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Lymph Nodes With Adequate Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Topics Discussed Between Parent and Child
Endpoint domain: Life impact
Endpoint subdomain: Communication
Primary endpoint: Pharmacokinetics of mirabegron and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ADAS-cog/11 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in CIBIC-plus scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in neurocognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Urticaria Control Test (UCT) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of nutrition information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to the duration of endobronchial intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 30 Days Perioperative Morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Reference diagnosis of MDS or CMML
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Video-fluoroscopy outcome parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee joint loading outcome parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Total Score of Rhinoconjunctivitis Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent of Eligible Justice Involved Persons initiated and on MOUD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Prescribers using MOUD
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Minutes of moderate to vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Brain-derived neurotrophic factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Population prevalence of Lymphatic Filariasis
Endpoint domain: Mortality/survival
Primary endpoint: Population prevalence of Yaws
Endpoint domain: Mortality/survival
Primary endpoint: Population prevalence of Buruli Ulcer
Endpoint domain: Mortality/survival
Primary endpoint: Negative stool culture for Carbapenem resistant Klebsiella pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum Bactericidal Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: toxicity of WT1 peptide-specific T-cells
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of OFF time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Freedom From AF/AFL/AT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Procedure and/or Device-related Cardiovascular SAE/SADEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Average TMC Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in oxidative stress biomarkers in PAD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in oxidative stress biomarkers in hypertensive patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalcy of diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in visual acuity at near
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from body mass index (BMI) at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Concentration of Canagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total volume of drain output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goodness of fit of pharmacokinetic modeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back specific functional status (Roland)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Numerical Rating Scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Vessel caliber
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in seated systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in seated diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent change in CGM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LM CE lesions at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CGM atrophy and LM inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in glycerol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in CRP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lipid profile (LDL, HDL and triglyceride concentrations)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Movement of the electrode post-operatively in millimetres
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change From Baseline in Fasting Triglyceride (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Swallowing related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (EORTC QLQ-C30, EORTC QLQ-CR38)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (EQ 5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: anatomic form and surface characteristics of the peri implant mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause Hospitalisations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of patients who gave their consent to participate in the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain Numerical Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: burning pain during application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Pediatric Rhinosinusitis Symptom Scale (PRSS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of GABHS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pathological interpretation of biopsy specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Exposure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical/pathological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) for ACR 20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Hart Dose (MHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month Hemoglobin Level Stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Experiencing Postoperative Nausea and Vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of discontinuation of systemic GCs without acute GvHD flare and without disease progression/recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of acute (and/or chronic) GvHD-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in level of p16 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of post-operative anterior knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion of knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Society and Knee Society function score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mitochondrial oxygen flux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic uptake and washout of 123-I MNI-187
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adaptation of fingertip forces and movements during grasping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hand function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative treatment failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 48-week cumulative virology failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractional synthetic rate (FSR) of myofibrillar muscle protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Therapeutic cure of tinea pedis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Patients Reporting Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Recovery (QoR) 40
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Urine Albumin/Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hemodynamic variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Embodiment of the Prosthetic limb
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Motor Reaction Time (MRT) Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition Reaction Time (RRT) Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Reaction Time (TRT) Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression severity measured by PHQ-9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in hemoglobin (Hb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pulmonary oxygen metabolism function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Visual analogue score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetic parameters of nalmefene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Simulated Thought Paradigm - Digit Categorization Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Simulated Thought Paradigm - Dichotic 1-Back Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Simulated Thought Paradigm - Body Map Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Mindful Awareness Task
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complement activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Onset of action of suxamethonium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from suxamethonium injection to laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of blood stage parasites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement of dystonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Clinical Benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health outcomes of infants exposed to Hydroxyurea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Comparative analysis of congenital malformations or medical conditions in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of participants receiving first-line systemic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement of diet program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of aspiration pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Time from end of sedation to extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate from Baseline in PNQ Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: %HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success rate of nerve sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 4-Week Continuous Abstinence Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning